Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip

Amber Tong

Jim Tananbaum was looking for a specific type of company, one with a genetics-driven platform, when he launched Foresite Capital’s first blank check company. And …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip

Amber Tong

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

US drugs rely heavily on ingredients made overseas, new report shows

Biotech seed rounds sink to lowest level in years as industry slump drags on

Pharma's wins and losses in Trump's sprawling executive order on drug prices

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Fore­site pulls Gem­i­ni Ther­a­peu­tics to Nas­daq in a quick $216M SPAC flip

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Foresite pulls Gemini Therapeutics to Nasdaq in a quick $216M SPAC flip